It is worth noting that administration site and drug delivery vehicles have previously provided dose‐sparing effects for infectious disease vaccines.[33] CD40 agonism essentially drives in situ vaccination against endogenous tumor antigen,[34] and thus CD40a therapy may exhibit similar dose‐sparing effects depending on drug delivery strategy. The gene discussed is CD40; the disease is neoplasm.